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Introduction: Catch-up growth following the cessation of a growth inhibiting cause occurs in humans and an-
imals. Although its underlying regulatory mechanisms are not well understood, current hypothesis confer an
increasing importance to local factors intrinsic to the long bones' growth plate (GP).
Aim: The present study was designed to analyze the growth-hormone (GH)-insulin-like growth factor I (IGF-
I) axis in the epiphyseal cartilage of young rats exhibiting catch-up growth as well as to evaluate the effect of
GH treatment on this process.
Material and methods: Female Sprague–Dawley rats were randomly grouped: controls (group C), 50% diet re-
striction for 3 days+refeeding (group CR); 50% diet restriction for 3 days+refeeding & GH treatment (group
CRGH). Analysis of GH receptor (GHR), IGF-I, IGF-I receptor (IGF-IR) and IGF binding protein 5 (IGFBP5) ex-
pressions by real-time PCR was performed in tibial growth plates extracted at the time of catch-up growth,
identiﬁed by osseous front advance greater than that of C animals.
Results: In the absence of GH treatment, catch-up growth was associated with increased IGF-I and IGFBP5
mRNA levels, without changes in GHR or IGF-IR. GH treatment maintained the overexpression of IGF-I
mRNA and induced an important increase in IGF-IR expression.
Conclusions: Catch-up growth that happens after diet restriction might be related with a dual stimulating
local effect of IGF-I in growth plate resulting from overexpression and increased bioavailability of IGF-I. GH
treatment further enhanced expression of IGF-IR which likely resulted in a potentiation of local IGF-I actions.
These ﬁndings point out to an important role of growth cartilage GH/IGF-I axis regulation in a rat model of
catch-up growth.© 2012 Elsevier Ltd. All rights reserved.1. Introduction
Longitudinal growth may be impaired in several chronic disorders
like inﬂammatory bowel diseases, juvenile idiopathic arthritis andmal-
nutrition as well as by exposure to some drugs. The term catch-up
growth, introduced by Prader et al. [1], describes the phenomenon by
which longitudinal growth velocity transiently stands above the statis-
tical limits of normality for age and/or maturity after the removal of a
growth-inhibiting condition. Catch-up growth occurs in humans and
animals and its underlying pathogenic mechanism is not clear [2,3]. A
recent hypothesis proposes an intrinsic essential mechanism for
catch-up growth in the long bones' growth plate [4].
Linear bone growth results from proliferation, hypertrophy and
matrix production of cartilage cells in growth plate, on whosenit, Department of Pediatrics,
3.
rights reserved.metaphyseal end, bone replaces the cartilage [5]. Growth plate of endo-
chondral bones is comprised of cells representing various states of
differentiation: the resting zone, the proliferative zone with actively
dividing cells, and the hypertrophic zone with maturing cells enlarging
and ultimately dying [6]. These proliferative and maturation processes
are induced by numerous systemic endocrine effectors such as circulat-
ing growth hormone (GH). The effects of GH are to a great extentmedi-
ated by the actions of insulin-like growth factor-I (IGF-I), a peptide
growth factor produced in great abundance by hepatic tissue, source
of the circulating plasma IGF-I [7], but also locally produced by chondro-
cytes. Likewise, growth hormone receptor (GHR) [8–10] have been
localized in several regions of the growth cartilage, demonstrating
that chondrocytes are capable of responding directly to GH in a para-
crineway. Cellular proliferation and apoptosis are carefully coordinated
processes within the growth plate. The GH axis is known to play a
critical role in proliferation and IGF-I is an identiﬁed regulator of
apoptosis in many tissues [11,12]. The interplay of proliferation and
apoptosis in the developing growth plate has only recently been
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are known to undergo apoptosis [13–18].
The regulation of longitudinal growth is inﬂuenced by numerous
systemic and local factors. Although the interplay among these factors
is still unclear [6], GH and IGF-I are crucial. CirculatingGH can act direct-
ly on growth plate stimulating the local IGF-I synthesis, which in turns
induces chondrocyte expansion [19]. Additionally, there are some evi-
dences that systemic IGF-I could also stimulate growth plate chondro-
cytes [20]. However, locally derived IGF-I seems to be more important
in longitudinal growth than systemic IGF-I [21]. Abnormalities of the
GH/IGF-I axis are one of the major determinants of growth retardation
in childrenwith chronic illnesses [22]. There are experimental and clin-
ical evidences demonstrating important alterations in GH/IGF-I axis
during chronic diseases, like chronic renal failure [23], chronic bowel
inﬂammatory diseases [24] and juvenile idiopathic arthritis [25]. It is
well known that treatment with GH potentiates catch-up growth in
several conditions [5,26]. The GH/IGF-I axis in the growth plate at the
time of catch-up growth was previously implicated by Gat-Yablonski
in a rodent model of food restriction [9]. Nevertheless, how catch-up
growth is inﬂuenced by GH treatment is largely unknown.
A previous experimental study of our group [5] examined the pat-
tern of catch-up growth in young rats after an inhibitory growth con-
dition. The existence of a growth recovery implies the return to the
previous growth path after noxious stimulus suppression. Our exper-
imental model showed that growth rate acceleration inherent to a
spontaneous catch-up, was associated with enhancement of prolifer-
ative activity, and specially, to an expansion of the hypertrophic zone
of the cartilage. GH administration started at the time of noxious
stimulus suppression, further accelerated catch-up growth velocity,
this effect being likely related to a greater enlargement of the termi-
nal chondrocyte height [5]. The study presented here used the
above mentioned animal model to determine if the ability to exhibit
catch-up growth and the effect of GH treatment on this process are
related to alterations in the growth plate GH-IGF-I axis modulation.
2. Materials and methods
2.1. Experimental protocol
Samples from animals used in a formerly published study were uti-
lized [5]. Brieﬂy, young female Sprague-Dawley rats (Harlam Iberia,
Barcelona, Spain) were acclimatized to the experimental area and
randomly grouped as follows: controls fed ad libitum (group C), diet
restriction for 3 days+refeeding (group CR), diet restriction for
3 days+refeeding & GH treatment (group CRGH). On days 11, 12 and
13 of the protocol, groups CR y CRGH received 50% of the average
daily food consumed by the same animals the previous three days.
CRGH animals were treated with 3.3 mg/kg/day recombinant human
GH (Norditropin, Novo Nordisk Pharm, Madrid-Spain) given by intra-
peritoneal route from day 14 on. Untreated animals received the same
volume of vehicle (saline). Rats were killed at different time points
after refeeding (n=5 rats each time). Catch-up growth, assessed by
measurement of osseous front advance by calcein labeling, was found in
CR and CRGH groups on day 21 (C: 164.5±7.7 μm; CR: 186.1±6.1 μm;
CRGH: 201.1±4.4 μm). Therefore, samples extracted on day 21 were
used for the study presented here. The study complied with current leg-
islation on animal experiments in the European Union and was ap-
proved by our Institution Ethics Committee for Investigation with
animals.
2.2. Samples
The proximal ends of both tibiae were obtained after sacriﬁce by
exsanguination under anesthesia. The dissection of growth plate
was performed with magnifying lens and a scalpel to allow removing
the adjacent bone zones accurately. The right tibiae were immediatelyfrozen in liquid nitrogen for mRNA studies and the left tibiae were em-
bedded in methylmethacrylate, ﬁxed in 4% paraformaldehyde (PFA)
and used for immunohistochemistry and in situ hybridization studies
on growth plate as previously described [27–29].
2.3. Immunohistochemistry
Immunohistochemical staining was performed in PFA-ﬁxed frontal
sections (5 μm thick) of proximal tibiae, using IGF-I and IGF binding
protein 5 (IGFBP5) polyclonal antibodies (Santa Cruz Biotechnology
Inc, CA, USA) as described elsewhere [27].
2.4. In situ Hybridization
IGF-I, GHR, IGF-I receptor (IGF-IR) and IGFBP-5 antisense and sense
RNA probes were supplied by Genedect (Genedetect.com, Bradenton,
FL, USA). The hybridization procedure was carried out as described
elsewhere [27]. Two parallel sections served as negative controls. One
section hybridized with a labeled sense riboprobe and a second section
was incubated adding a negative control probe to the hybridizationmix-
ture. No hybridization signal was found in any of these negative controls.
2.5. Real-time PCR
mRNA was extracted from frozen tibiae samples using modiﬁed
Chomczynski method [30]. RNA purity and integrity were assessed
by 260/280 ratio measurement using an ultra violet spectrophotome-
ter (Gene Quant Pro, Amersham Biosciences, GE Healthcare Spain) and
an 1.5% agarose gel respectively. Samples were diluted to 1 mg/ml, be-
fore reverse transcription,with a commercial kit (Qiagen Iberia,Madrid,
Spain).
GHR, IGF-I, IGF-IR and IGFBP5 expressionswere quantiﬁed by real-time
PCR system (One-Step, Applied Biosystems, Foster City, CA, USA) using
SYBR Green (ABgene Products, Thermo Fisher Scientiﬁc, Rockford, IL,
USA) as ﬂuorophore and β-actin as a housekeeping gene. For all the qPCR
experiments, melting curve showed a unique product that corresponded
with an exclusive temperature of DNA dissociation. Oligonucleotide primer
pairs were as follows: for β-actin, forward: ACCAGGGTGTGATGGTGGGTAT
and reverse: CGTCCCAGTTGACAATGC; for GHR, forward: AATTAATC-
CAAGCCTGAGGGAAA and reverse: GGAACGACACTTGGT GAATCG; for IGF-I,
forward: TACCAGCTCGGCCACAGC and reverse: GTGGGCTTGTTGAAG-
TAAAAGC; for IGF-IR, forward: GCTGCTGGACCACAAATCG and reverse:
TCGCTTCCCACACACACTTG; for IGFBP5, forward: GACCAAGGCCCCTGCCGCA
and reverse: CACAGTTGGGCAGGTACACGGC. Primer sequences were
designed with the Primer Express software (Perkin–Elmer Applied Biosys-
tems) and synthesized by Invitrogen (Fisher-Invitrogen, Barcelona, Spain).
Standard curves were obtained for each primer pair with efﬁciency near
to 0.99. Afterwards, qPCR analysis was performed by ΔΔCt values.
2.6. Statistical analysis
Results are given as mean±SEM and groups were compared
using one-way ANOVA. When the normality test failed, ANOVA on
ranks was used. When treatments were signiﬁcantly different,
Dunn's test and the Holm–Sidak method were used to perform pair-
wise multiple comparisons. Statistical signiﬁcance was set at a two-
tailed value of Pb0.05.
3. Results
3.1. C and CR groups
3.1.1. Immunohistochemical analysis
Analysis of IGF-I and IGFBP5 by immunohistochemical technique
showed no variations between C and CR groups for the distribution pat-
tern. The positive signals for both peptides were largely restrained to
Table 1
Relative fold change obtained by real time PCR for GHR, IGF-I, IGF-IR and IGFBP5 mRNAs
in the tibial growth plate of the three groups of rats.
GHR IGF-I IGF-IR IGFBP5
C 1.00±0.176 1.00±0.03 1.00±0.25 1.00±0.10
CR 0.87±0.116 2.32±0.78 α 0.85±0.28 1.47±0.23 α
CRGH 0.87±0.102 2.53±0.57 α 2.34±0.12 α,β 1.36±0.21 α
Legend: C group— control animals; CR group— animals submitted to the noxious stim-
ulus; CRGH group — animals submitted to the noxious stimulus treated with growth
hormone.
GHR: Growth Hormone Receptor; IGF-I: Insulin-like Growth Factor-I; IGF-IR: Insulin-
like Growth Factor-I Receptor; IGFBP5: Insulin-like Growth Factor Binding Protein 5.
Data are mean±SEM. Superscripts α and βmean signiﬁcantly different (Pb0.05) from
C and CR group, respectively.
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the lower part of the proliferative zone (LPZ) only in the CR group.
3.1.2. In situ hybridization assay
The pattern of mRNA signaling distribution in C and CR groups for
IGF-I, IGF-IR and IGFBP5 was similar to that described for the pep-
tides. Positive cells were mostly present in the HZ stratum. Some
cells sited in the LPZ were positive for IGF-I mRNA in the CR group
(Fig. 1). GHR mRNA was located in the entire growth plate with no
differences between groups (data not shown).
3.1.3. Real time PCR
Relative quantiﬁcation of GHR and IGF-IR mRNA revealed no
changes in CR group compared with C animals. However, levels of
IGF-I and IGFBP5 mRNAs were higher in CR than C rats (Table 1).
3.2. Effect of GH treatment
No variations were found in the distribution pattern observed by
immunohistochemical or in situ hybridization assays for IGF-I, IGF-
IR, GHR or IGFBP5, compared with the CR group. However, GH treat-
ment induced a signiﬁcant overexpression of IGF-IR mRNA compared
with CR group (Table 1) (Fig. 2).
4. Discussion
Several experimental models of catch-up growth have been
described, differing in the timing and nature of the noxius stimulus for
growth retardation. Food restriction is a widely used model in rodents.
In the present study we used catch-up growth after diet restriction
during 3 days. We previously demonstrated that this period of food
restriction was associated with stimulated proliferation and greater
hypertrophy of growth cartilage chondrocytes, as formerly described
[16]. The present study characterizes local expression of GHR, IGF-I,
IGF-IR, IGFBP5 during catch-up growth phenomenon and its modula-
tion by growth hormone treatment. Moreover, the study offers someFig. 1. Representative examples of in situ hybridization for IGF-I, IGFBP5 and IGF-IR mRNAs
ious stimulus (CR group), and animals submitted to the noxious stimulus treated with gro
Growth Factor Binding Protein 5; IGF-IR: Insulin-like Growth Factor-I Receptor.insight into the molecular mechanisms underlying catch-up growth.
Our ﬁndings indicate that IGF-I and IGFBP5mRNAswere overexpressed
in the tibial growth plates of the group of rats exhibiting catch-up
growth. These results are in agreement with the ﬁndings from Gat-
Yablonski et al. that demonstrated that catch-up growth after 10 days
of food restrictionwas associatedwith an increase in local protein levels
of IGF-IR and in serum levels of IGF-I [9,31].
It has been described that IGFBP5, enhances IGF-I-driven chondro-
cyte proliferation, thereby better presenting it to its receptor [32].
Delivery of IGF-I from pools of IGF-I bound to low-afﬁnity IGFBP-5 in
extracellular matrix could potentiate the binding of ligand to the
IGF-IR on the cell surface, enhancing the differentiation process medi-
ated by the IGF-I. The observed coexistent elevation of IGFBP5 and IGF-
I likely facilitates bioavailability of local IGF-I [33] so that it can be
hypothesized that stimulated paracrine and autocrine actions of IGF-
I are linked to the morphological and dynamic changes that take
place in the chondrocytes at the time of catch-up growth and to the
ensuing acceleration of longitudinal growth velocity.
The present study also shows that catch-up growth was not associ-
ated with signiﬁcant modiﬁcations in the pattern of expression of GH-
IGF-I growth plate axis when assessed by immunohistochemistry or infor the three studied groups: control animals (C group), animals submitted to the nox-
wth hormone (CRGH group). IGF-I: Insulin-like Growth Factor-I; IGFBP5: Insulin-like
Fig. 2. Representative examples of immunohistochemistry for IGF-I and IGFBP5 for the three studied groups: control animals (C group), animals submitted to the noxious stimulus
(CR group), and animals submitted to the noxious stimulus treated with growth hormone (CRGH group). A negative control is also presented. IGF-I: Insulin-like Growth Factor-I;
IGFBP5: Insulin-like Growth Factor Binding Protein 5.
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signaling between C and CR groups does not invalidate the quantitative
changes detected by real time PCR because immunohistochemistry and
in situ hybridization are good techniques for exploring changes in the
spatial distribution of peptides and mRNAs, respectively, but not for
measuring modiﬁcations in the magnitude of expression. For RNA ex-
traction of the growth plate, we used manual microdissection. This is
a simple and reliable method that minimized the contamination from
surrounding tissues that can also express genes fromGH/IGF-I axis [34].
Treatment with recombinant human GH has been widely used in
several pediatric diseases associated with short stature and poor
growth [35]. GH effects on epiphyseal cartilage chondrocyte prolifera-
tion are still controversial. GH can act directly on growth plate by
increasing chondrocyte proliferation and stimulating local production
of IGF-I [36]. In the present study we demonstrated that GH treatment
did not modify the overexpression of IGF-I mRNA in the growth carti-
lage chondrocytes associated to the spontaneous catch-up growth of
CR group. By contrast, we found that GH treatment induced an impor-
tant increase in the growth plate IGF-IR expression These results rein-
force the theory that therapy with GH potentiates catch-up growth by
activating local IGF-I axis and support the crucial role of IGF-I locally
produced in the long bones' growth plate in the postnatal growth [21].
The role of GH in the proliferation of epiphyseal cartilage chondro-
cytes is a matter of debate [37,38]. The microscopic examination of the
in situ hybridization specimens suggested that the expression of IGF-I
mRNA extended to the proliferative zone in the CR and CRGH groups.
These ﬁndings together with the results of the real time PCR analysis in-
dicate that the phenomenon of catch-up growth, either spontaneous or
magniﬁed by GH treatment, is associated with local stimulation of IGF-I
in the growth plate. This is also in agreement with Isaksson et al. who
demonstrated that local IGF-I ampliﬁcation by GH stimulates chondro-
cyte proliferation and hypertrophy, contributing to bone growth. [19].
In summary, the present study shows for the ﬁrst time that catch-
up growth that occurs after a short period of food restriction is asso-
ciated with an increased expression of IGF-I and IGFBP5 in the long
bones’ growth plate. GH treatment preserves these changes and pre-
sumably potentiates local IGF-I actions by increasing IGF-IR expres-
sion in the chondrocytes.References
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